Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Ultragenyx Pharmaceutical Inc. RARE

Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older.


Recent & Breaking News (NDAQ:RARE)

Ultragenyx Announces Completion of Enrollment in Phase 3 Study of Aceneuramic Acid Extended Release (Ace-ER) in GNE Myopathy

GlobeNewswire July 27, 2016

A Peek Into The Markets: U.S. Stock Futures Edge Higher Ahead Of Bank Earnings

Benzinga.com  July 15, 2016

Ultragenyx's Final Stage Study Of Recombinant Human Beta-Glucuronidase Meets Primary Endpoint

Benzinga.com  July 15, 2016

Ultragenyx Announces Positive Topline Data from Phase 3 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7

GlobeNewswire July 14, 2016

Ultragenyx to Present Phase 3 Data for Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7 (MPS 7) at 14th International Symposium on MPS and Related Diseases

GlobeNewswire July 13, 2016

Pre-Market Review on Biotechnology Equities -- Northwest Biotherapeutics, Titan Pharma, Ultragenyx Pharma, and Athersys

PR Newswire June 29, 2016

Ultragenyx Receives Breakthrough Therapy Designation for KRN23 in Pediatric Patients with X-Linked Hypophosphatemia

GlobeNewswire June 28, 2016

Ultragenyx Appoints Karah Parschauer as Executive Vice President, General Counsel

GlobeNewswire June 20, 2016

Chief Medical Officer Resignation Will Not Affect Ultragenyx's Catalyst-Rich Timeline

Benzinga.com  June 17, 2016

Ultragenyx and Takeda enter into a Collaboration to Develop and Commercialize Therapies for Rare Genetic Diseases

GlobeNewswire June 7, 2016

Ultragenyx to Present at Upcoming Investor Conferences

GlobeNewswire June 1, 2016